Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00712348 · ClinicalTrials.gov registry record · Phase 3
Switchover Trial From Imiglucerase to Plant Cell Expressed Recombinant Human Glucocerebrosidase
A Phase 3 study of Gaucher Disease, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 31
- Enrollment target
- 10
- Study locations
NCT00712348 is a Phase 3 study of Gaucher Disease that has completed, run by Pfizer. The registered enrollment target is 31 participants, below the 1,056-participant average among 13 other Gaucher Disease trials with a reported enrollment target (97% lower). The trial reports 10 study locations across 6 states.
The verdict
NCT00712348, a Phase 3 study of Gaucher Disease, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 31 participants
- Enrollment target
- 10
- Study locations
Study Summary
This is a multi-center, open-label, switchover trial to assess the safety of taliglucerase alfa in 30 patients with Gaucher disease who are currently being treated with imiglucerase (Cerezyme®) enzyme replacement therapy.
Conditions Studied
Interventions
- DRUG Taliglucerase alfa
Study Locations (10)
Other
- Rambam Medical Center - Haifa
- Shaare Zedek Medical Center - Jerusalem
- Sala de Hematologia, Hospital Universitario Miguel Servet - Zaragoza
- Lysosomal Disorders Service, Addenbrookes Hospital NHS Trust - Cambridge
- Royal Free Hospital - London
Florida
- University Research Foundation for Lysosomal Storage Diseases, Inc. - Coral Springs
Georgia
- Department of Human Genetics, Emory University School of Medicine - Decatur
New York
- Neurogenetics, NYU at Rivergate - New York
Victoria
- Bone Marrow Transplant Service, The Royal Melbourne Hospital - Parkville
Ontario
- Mount Sinai Hospital - Toronto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2008-12 |
| Est. Completion | 2013-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00712348
The ClinicalTrials.gov registry entry for NCT00712348 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,056-participant average among 13 other Gaucher Disease trials with a reported enrollment target (97% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Gaucher Disease appearing as the primary indexed condition, and to 1 intervention - of which Taliglucerase alfa is the first listed.
NCT00712348 reports 10 study locations spanning 6 distinct geographic areas - top geographies include Other, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT00712348 about?
NCT00712348 is a clinical study titled "Switchover Trial From Imiglucerase to Plant Cell Expressed Recombinant Human Glucocerebrosidase". This is a multi-center, open-label, switchover trial to assess the safety of taliglucerase alfa in 30 patients with Gaucher disease who are currently being treated with imiglucerase (Cerezyme®) enzyme replacement therapy.
What is the current status of trial NCT00712348?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 31 participants. The study started on 2008-12. Estimated completion is 2013-05.
What conditions does trial NCT00712348 study?
This clinical trial studies the following conditions: Gaucher Disease.
What interventions are being tested in trial NCT00712348?
The interventions under investigation include: Taliglucerase alfa (DRUG).
Who is sponsoring clinical trial NCT00712348?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00712348 being conducted?
This trial has 10 study locations across Florida, Georgia, New York, Victoria, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gaucher Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase III Trial to Assess the Safety and Efficacy of Plant Cell Expressed GCD in Patients With Gaucher Disease
COMPLETED · Phase 3
-
Extracellular Vesicles as Potential Biomarkers and Therapeutic Target in Gaucher Disease
RECRUITING
-
A Long-term Follow-up Study of Gaucher Disease
RECRUITING
-
Gaucher Disease Outcome Survey (GOS)
RECRUITING
-
International Collaborative Gaucher Group (ICGG) Gaucher Disease Registry & Pregnancy Sub-registry
RECRUITING
-
The GBA Multimodal Study in Parkinson's Disease
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.